Studies how anti-IL-17 treatment affects airway tightness in adults
Observes airway changes in adults with skin or joint disease starting anti-IL-17 treatment.
Plain-language title generated from the registry record
Registry title: The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance
Key facts
- Where
- Hvidovre, DenmarkSee the site
Where in Denmark
- Respiratory Research Unit Hvidovre Department of Respiratory Medicine, Copenhagen University HospitalHvidovre, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Copenhagen University Hospital, Hvidovre
- Trial code
- NCT06224634
- Record updated
- 18 March 2025
- Original description
This observational longitudinal cohort study aims to assess the effect of monoclonal antibodies targeting interleukin 17 (anti-IL-17) on airway hyperreactivity and airway resistance. The study involves adult participants suffering from dermatological or rheumatological illness, who are planning to start treatment with monoclonal antibodies targeting interleukin 17 as a part of the treatment of these diseases.Read full original descriptionShow less
The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance: a Longitudinal Cohort Study
This observational longitudinal cohort study aims to assess the effect of monoclonal antibodies targeting interleukin 17 (anti-IL-17) on airway hyperreactivity and airway resistance. The study involves adult participants suffering from dermatological or rheumatological illness, who are planning to start treatment with monoclonal antibodies targeting interleukin 17 as a part of the treatment of these diseases.
The primary outcome of this study will be changes in airway hyperresponsiveness to methacholine challenge reported as response-dose-ratio before and after initiation of anti-IL17 treatment regardless of presence of respiratory disease. Furthermore, the potential effect of anti-IL-17 on airway resistance will be assessed using conventional spirometry for measuring changes in FEV1 and Airwave oscillometry.
A reduced degree of airway hyperreactivity and airway resistance after initiating ani-IL-17 could indicate effectiveness of anti-IL-17 in asthma patients which would have to be examined further in a population of asthma patients.
Inclusion: Patients planning to start treatment with anti-IL-17 antibodies.
Exclusion: Previous anaphylactic shock or severe allergic reaction to medicine; Recent eye surgery or risk of elevated intracranial pressure; Treatment with systemic corticosteroids within 6 weeks; Uncontrolled hypertension; Myocardial infarction or stroke within the last 3 months; Current pregnancy; FEV1 < 1.5L or less than 60% of predicted value expected; Known aortic aneurysm.